The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin

Nagendra Pokala, Beverley Adams-Huet, Xilong Li, Lindsay B. Harrison, Anna Vanderheiden, Ildiko Lingvay

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In patients requiring high-dose insulin treatment, a randomized, double-blind, placebo-controlled study showed that liraglutide improved glycaemic control and treatment satisfaction while promoting weight loss. We performed a post hoc analysis to evaluate if patients’ baseline characteristics impact the efficacy of liraglutide, and which outcomes correlate with treatment satisfaction. We used regression analysis to model the change in HbA1c and weight, with treatment assignment and baseline characteristics [HbA1c, age, body mass index (BMI), total daily dose (TDD) of insulin, duration of insulin treatment, and type of insulin regimen] as independent variables. Improvement in HbA1c was best predicted by treatment with liraglutide, followed by higher baseline HbA1c, BMI and age. Changes in weight were only associated with liraglutide treatment, independent of all baseline characteristics. Improvement in HbA1c was the only significant predictor of improvement in treatment satisfaction, while weight loss, change in TDD of insulin and rate of hypoglycaemia did not influence treatment satisfaction. In patients treated with high-dose insulin, liraglutide significantly improved glycaemic control and led to weight loss regardless of patients’ baseline characteristics. Improvement in HbA1c was the most important predictor of patients’ treatment satisfaction.

Original languageEnglish (US)
Pages (from-to)1454-1457
Number of pages4
JournalDiabetes, Obesity and Metabolism
Volume19
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Insulin
Therapeutics
Weight Loss
Body Mass Index
Liraglutide
Weights and Measures
Patient Satisfaction
Hypoglycemia
Placebos
Regression Analysis

Keywords

  • antidiabetic drug
  • GLP-1 analogue
  • glycaemic control
  • insulin resistance
  • liraglutide

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin. / Pokala, Nagendra; Adams-Huet, Beverley; Li, Xilong; Harrison, Lindsay B.; Vanderheiden, Anna; Lingvay, Ildiko.

In: Diabetes, Obesity and Metabolism, Vol. 19, No. 10, 01.10.2017, p. 1454-1457.

Research output: Contribution to journalArticle

Pokala, Nagendra ; Adams-Huet, Beverley ; Li, Xilong ; Harrison, Lindsay B. ; Vanderheiden, Anna ; Lingvay, Ildiko. / The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin. In: Diabetes, Obesity and Metabolism. 2017 ; Vol. 19, No. 10. pp. 1454-1457.
@article{3a957d10692148279c68ca7eb83e672b,
title = "The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin",
abstract = "In patients requiring high-dose insulin treatment, a randomized, double-blind, placebo-controlled study showed that liraglutide improved glycaemic control and treatment satisfaction while promoting weight loss. We performed a post hoc analysis to evaluate if patients’ baseline characteristics impact the efficacy of liraglutide, and which outcomes correlate with treatment satisfaction. We used regression analysis to model the change in HbA1c and weight, with treatment assignment and baseline characteristics [HbA1c, age, body mass index (BMI), total daily dose (TDD) of insulin, duration of insulin treatment, and type of insulin regimen] as independent variables. Improvement in HbA1c was best predicted by treatment with liraglutide, followed by higher baseline HbA1c, BMI and age. Changes in weight were only associated with liraglutide treatment, independent of all baseline characteristics. Improvement in HbA1c was the only significant predictor of improvement in treatment satisfaction, while weight loss, change in TDD of insulin and rate of hypoglycaemia did not influence treatment satisfaction. In patients treated with high-dose insulin, liraglutide significantly improved glycaemic control and led to weight loss regardless of patients’ baseline characteristics. Improvement in HbA1c was the most important predictor of patients’ treatment satisfaction.",
keywords = "antidiabetic drug, GLP-1 analogue, glycaemic control, insulin resistance, liraglutide",
author = "Nagendra Pokala and Beverley Adams-Huet and Xilong Li and Harrison, {Lindsay B.} and Anna Vanderheiden and Ildiko Lingvay",
year = "2017",
month = "10",
day = "1",
doi = "10.1111/dom.12939",
language = "English (US)",
volume = "19",
pages = "1454--1457",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin

AU - Pokala, Nagendra

AU - Adams-Huet, Beverley

AU - Li, Xilong

AU - Harrison, Lindsay B.

AU - Vanderheiden, Anna

AU - Lingvay, Ildiko

PY - 2017/10/1

Y1 - 2017/10/1

N2 - In patients requiring high-dose insulin treatment, a randomized, double-blind, placebo-controlled study showed that liraglutide improved glycaemic control and treatment satisfaction while promoting weight loss. We performed a post hoc analysis to evaluate if patients’ baseline characteristics impact the efficacy of liraglutide, and which outcomes correlate with treatment satisfaction. We used regression analysis to model the change in HbA1c and weight, with treatment assignment and baseline characteristics [HbA1c, age, body mass index (BMI), total daily dose (TDD) of insulin, duration of insulin treatment, and type of insulin regimen] as independent variables. Improvement in HbA1c was best predicted by treatment with liraglutide, followed by higher baseline HbA1c, BMI and age. Changes in weight were only associated with liraglutide treatment, independent of all baseline characteristics. Improvement in HbA1c was the only significant predictor of improvement in treatment satisfaction, while weight loss, change in TDD of insulin and rate of hypoglycaemia did not influence treatment satisfaction. In patients treated with high-dose insulin, liraglutide significantly improved glycaemic control and led to weight loss regardless of patients’ baseline characteristics. Improvement in HbA1c was the most important predictor of patients’ treatment satisfaction.

AB - In patients requiring high-dose insulin treatment, a randomized, double-blind, placebo-controlled study showed that liraglutide improved glycaemic control and treatment satisfaction while promoting weight loss. We performed a post hoc analysis to evaluate if patients’ baseline characteristics impact the efficacy of liraglutide, and which outcomes correlate with treatment satisfaction. We used regression analysis to model the change in HbA1c and weight, with treatment assignment and baseline characteristics [HbA1c, age, body mass index (BMI), total daily dose (TDD) of insulin, duration of insulin treatment, and type of insulin regimen] as independent variables. Improvement in HbA1c was best predicted by treatment with liraglutide, followed by higher baseline HbA1c, BMI and age. Changes in weight were only associated with liraglutide treatment, independent of all baseline characteristics. Improvement in HbA1c was the only significant predictor of improvement in treatment satisfaction, while weight loss, change in TDD of insulin and rate of hypoglycaemia did not influence treatment satisfaction. In patients treated with high-dose insulin, liraglutide significantly improved glycaemic control and led to weight loss regardless of patients’ baseline characteristics. Improvement in HbA1c was the most important predictor of patients’ treatment satisfaction.

KW - antidiabetic drug

KW - GLP-1 analogue

KW - glycaemic control

KW - insulin resistance

KW - liraglutide

UR - http://www.scopus.com/inward/record.url?scp=85029821040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029821040&partnerID=8YFLogxK

U2 - 10.1111/dom.12939

DO - 10.1111/dom.12939

M3 - Article

C2 - 28608447

AN - SCOPUS:85029821040

VL - 19

SP - 1454

EP - 1457

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 10

ER -